8LY Stock Chart & Stats
€0.59
-€0.02(-7.82%)
At close: 4:00 PM EST
€0.59
-€0.02(-7.82%)
Day’s Range― - ―
52-Week Range€0.45 - €0.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.75M
Enterprise Value€112.91M
Total Cash (Recent Filing)€935.00K
Total Debt (Recent Filing)€7.50M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding14,048,068
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio-6.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€924.04K
Bulls Say, Bears Say
Bulls Say
Focused Product PipelineOncoZenge is singularly focused on BupiZenge™, a therapy addressing oral mucositis pain in chemotherapy/radiotherapy patients. A narrow, clinically specific indication concentrates R&D and regulatory effort, improving the prospect of commercial clarity and sustainable niche demand from oncology supportive care.
Built-in Commercialization/licensing ModelThe company’s stated model emphasizes partner licensing and targeted commercialization, enabling capital-efficient market access. Strategic out-licensing can transfer regulatory, distribution, and sales costs to larger pharma, providing milestone and royalty streams that scale without large incremental capex for OncoZenge.
Positive Gross Profit In TTMReported positive gross profit suggests product-level economics can be viable once sales scale. If variable costs are covered, incremental revenue contributes positively to margins, meaning successful commercialization or licensing could rapidly improve overall profitability without requiring proportionate increases in operating leverage.
Bears Say
Minimal Revenue, Large LossesExtremely low revenue versus very large operating losses implies the company is pre-commercial or failing to monetize its asset. Persistent large losses erode equity, force repeated financing, and make sustaining R&D and commercialization initiatives difficult without external funding, a structural business risk.
Elevated Leverage And Thin EquityA sharp move from zero debt to meaningful borrowings leaves the balance sheet highly leveraged. Very thin equity reduces flexibility, raises refinancing and covenant risk, and increases interest obligations, constraining capacity to absorb setbacks or invest in commercialization without dilutive or costly financing.
Severe Revenue ContractionA near-total decline in reported revenue versus the prior period signals structural challenges in commercialization, market access, or recognition of sales. Such steep contraction undermines confidence in market adoption, prolongs reliance on external capital, and weakens the case for scaling operations or partnering on favorable terms.
OncoZenge AB News
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €7.75M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 37 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on May 20, 2026. The company reported -€0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.05.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 14,048,068 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.407%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Technical Analysis
―
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―